中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院副院長(cháng)、北京協和醫(yī)學(xué)院副校長(cháng)，系統醫(yī)學(xué)研究院院長(cháng)/蘇州系統醫(yī)學(xué)研究所所長(cháng)，中(zhōng)法新(xīn)發病原體(tǐ)聯合實驗室主任。中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院學(xué)部委員。
 國(guó)家傑出青年科(kē)學(xué)基金獲得者、教育部長(cháng)江學(xué)者特聘教授、國(guó)家“萬人計劃”首批科(kē)技(jì )創新(xīn)領軍人才、國(guó)家自然科(kē)學(xué)基金委創新(xīn)研究群體(tǐ)負責人、教育部創新(xīn)團隊帶頭人，榮獲全國(guó)優秀科(kē)技(jì )工(gōng)作(zuò)者、全國(guó)科(kē)技(jì )系統抗擊新(xīn)冠疫情先進個人、第三屆全國(guó)創新(xīn)争先獎狀、第二十三屆吳階平-保羅·楊森醫(yī)學(xué)藥學(xué)獎等多(duō)項榮譽。
  “十三五”計劃“艾滋病和病毒性肝炎等重大傳染病防治”科(kē)技(jì )重大專項總體(tǐ)組成員、國(guó)家“生物(wù)安(ān)全關鍵技(jì )術研發”重點專項專家組成員。“十四五”“病原學(xué)與防疫技(jì )術”“生物(wù)大分(fēn)子與微生物(wù)組”“生物(wù)安(ān)全關鍵技(jì )術研發”以及科(kē)技(jì )基礎資源調查等國(guó)家重點專項專家組成員。國(guó)務(wù)院第八屆學(xué)科(kē)評議組成員。北京市第七屆自然科(kē)學(xué)基金委員會委員。教育部病毒學(xué)領域知識體(tǐ)系建設專家組組長(cháng)。中(zhōng)華預防醫(yī)學(xué)會第六屆理(lǐ)事會常務(wù)理(lǐ)事兼生物(wù)信息學(xué)分(fēn)會主任委員，中(zhōng)華醫(yī)學(xué)會第二十六屆理(lǐ)事會常務(wù)理(lǐ)事兼醫(yī)學(xué)病毒學(xué)分(fēn)會副主任委員，上海證券交易所第二屆科(kē)技(jì )創新(xīn)咨詢委員會委員。Biosafety & Health雜志(zhì)執行主編，Frontiers in Microbiology、Chin Med J、《中(zhōng)華微生物(wù)與免疫學(xué)雜志(zhì)》副主編。
先後承擔國(guó)家863計劃、973計劃、科(kē)技(jì )重大專項、國(guó)家自然科(kē)學(xué)基金等科(kē)研項目10餘項。作(zuò)為(wèi)通訊作(zuò)者（共同通訊作(zuò)者）在Cell、Lancet、Lancet Microbe、Cell Host Microbe、Lancet Resp Med、Am J Resp Crit Care Med、Cell Res、PNAS 等雜志(zhì)發表SCI論文(wén)160餘篇，被引用(yòng)逾8.3萬次（Google Scholar數據），被多(duō)部國(guó)際指南、國(guó)際專利和國(guó)際政策文(wén)件參引。2020-2022年度連續入選愛思唯爾中(zhōng)國(guó)高被引學(xué)者榜單，2022年度入選科(kē)睿唯安(ān)全球高被引科(kē)學(xué)家以及斯坦福大學(xué)全球前2%頂尖科(kē)學(xué)家榜單。
獲省部級及以上科(kē)技(jì )獎勵7項。研究成果入選“中(zhōng)國(guó)2020年度生命科(kē)學(xué)十大進展”、2020年度“中(zhōng)國(guó)十大醫(yī)學(xué)科(kē)技(jì )新(xīn)聞”、2020年度“十大醫(yī)學(xué)進展”、“中(zhōng)國(guó)2020年度重要醫(yī)學(xué)進展”（3項）、“中(zhōng)國(guó)2021年度重要醫(yī)學(xué)進展”（2項）、“中(zhōng)國(guó)2022年度重要醫(yī)學(xué)進展”（1項）、2020年Springer Nature中(zhōng)國(guó)學(xué)者年度高影響力研究。5篇論文(wén)入選2020、2021年度中(zhōng)國(guó)百篇最具(jù)影響國(guó)際學(xué)術論文(wén)。

呼吸道病毒感染緻病機制及幹預研究

1.    醫(yī)學(xué)病毒學(xué)“醫(yī)學(xué)病毒學(xué)（病毒變異與感染緻病機制）”，國(guó)家自然基金委創新(xīn)研究群體(tǐ)項目（82221004），2023.01~2027.12，1000萬元，項目負責人
2.    “重要腸道病毒感染複制關鍵宿主因子全景式篩選及其作(zuò)用(yòng)分(fēn)子機制研究”，國(guó)家自然科(kē)學(xué)基金重點項目（81930063），2020.01~2024.12，297萬元，項目負責人
3.    “重要新(xīn)發突發傳染病生物(wù)安(ān)全基礎與防控技(jì )術研究”，醫(yī)學(xué)與健康科(kē)技(jì )創新(xīn)工(gōng)程項目，2016.10~2020.12，1100萬元，首席專家
4.    國(guó)際合作(zuò)項目“新(xīn)發病原體(tǐ)研究”， 2022.4~2027.3，150萬歐元，項目負責人

（一）代表性論文(wén) 
以通訊作(zuò)者（含共同）身份發表論文(wén)約160餘篇，代表性論文(wén)【# first authors,*corresponding author】：
1.    Zhang D#, Qiao L#, Lei X#, Dong X, Tong Y, Wang J*, Wang Z*, Zhou R*. Mutagenesis and structural studies reveal the basis for the specific binding of SARS-CoV-2 SL3 RNA element with human TIA1 protein. Nat Commun. 2023 Jun 22; 14(1): 3715.
2.    Guo L#, Zhang Q#, Zhang C, Huang T, Ren L, Cao B*, Wang J*. Assessment of Antibody and T-Cell Responses to the SARS-CoV-2 Virus and Omicron Variant in Unvaccinated Individuals Recovered From COVID-19 Infection in Wuhan, China. JAMA Network Open. 2022 Apr 1;5(4): e229199.
3.    Guo S#, Lei X#, Chang Y#, Zhao J#, Wang J#, Dong X, Liu Q, Zhang Z, Wang L, Yi D, Ma L, Li Q, Zhang Y, Ding J, Liang C, Li X, Guo F*, Wang J*, Cen S*. SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis. Signal Transduct Target Ther. 2022 Dec 27;7(1):400.
4.    Zhang S#, Huang W#, Ren L#, Ju X#, Gong M#, Rao J#, Sun L, Li P, Ding Q*, Wang J*, Zhang QC*. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 2022 Jan; 32(1):9-23.
5.    Wu Z, Jin Q, Wu G, Lu J, Li M, Guo D, Lan K, Feng L, Qian Z, Ren L, Tan W, Xu W, Yang W, Wang J*, Wang C. SARS-CoV-2's origin should be investigated world wide for pandemic prevention. Lancet. 2021 Oct 9;398(10308):1299-1303. 
6.     Huang L#, Yao Q#, Gu X#, Wang Q#, Ren L#, Wang Y#, Hu P#, Guo L#, Liu M, Xu J, Zhang X, Qu Y, Fan Y, Li X, Li C, Yu T, Xia J, Wei M, Chen L, Li Y, Xiao F, Liu D, Wang J*, Wang X*, Cao B*. 1-year outcomes in hospital survivors with COVID-19: alongitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-758. 
7.    Liu X#, Xu F#, Ren L#, Zhao F, Huang Y, Wei L, Wang Y, Wang C, Fan Z, Mei S, Song J, Zhao Z, Cen S, Liang C, Wang J*, Guo F*. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Nat Commun. 2021 Jul 20;12(1):4427.
8.    Cao C#, Cai Z#, Xiao X#, Rao J, Chen J, Hu N, Yang M, Xing X, Wang Y, Li M, Zhou B, Wang X, Wang J*, Xue Y*. The architecture of the SARS-CoV-2 RNA genome inside virion. Nat Commun. 2021 Jun 24;12(1):3917.
9.    He Z#, Ren L#, Yang J#, Guo L#, Feng L#, Ma C, Wang X, Leng Z, Tong X, Zhou W, Wang G, Zhang T, Guo Y, Wu C, Wang Q, Liu M, Wang C, Jia M, Hu X, Wang Y, Zhang X, Hu R, Zhong J, Yang J, Dai J, Chen L, Zhou X, Wang J*, Yang W*, Wang C*. Seroprevalence and humoral immune durability ofanti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021 Mar 20;397(10279):1075-1084.
10.    Sun L#, Li P#, Ju X#, Rao J#, Huang W, Ren L, Zhang S, Xiong T, Xu K, Zhou X, Gong M, Miska E, Ding Q*, Wang J*, Zhang QC*. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. Cell. 2021 Feb 9: S0092-8674(21)00158-6.
11.    Zhang C#, Li W#, Lei X, Xie Z, Qi L, Wang H, Xiao X, Xiao J, Zheng Y, Dong C, Zheng X, Chen S, Chen J, Sun B, Qin J, Zhai Q, Li J, Wei B*, Wang J*, Wang H*. Targeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity. Sci Adv. 2021 Sep 17;7(38): eabb5933.
12.    Zhang T#, Yang Y#, Xiang Z#, Gao CC#, Wang W, Wang C, Xiao X, Wang X, Qiu WN, Li WJ, Ren L, Li M, Zhao YL, Chen YS*, Wang J*, Yang YG*. N6-methyladenosine regulates RNA abundance of SARS-CoV-2. Cell Discov. 2021 Jan 28;7(1):7.
13.    Zhu Y#, Yu D#, Han Y#, Yan H, Chong H, Ren L, Wang J*, Li T*, He Y*. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 2020 Nov 6;6(45): eabc9999.
14.    Huang C#, Huang L#, Wang Y#, Li X#, Ren L#, Gu X#, Kang L#, Guo L#, Liu M#, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J*, Zhang D*, Cao B*. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023 Jun 17;401(10393): e21-e33.
15.    Chi X#, Liu X#, Wang C#, Zhang X, Li X, Hou J, Ren L, Jin Q*, Wang J*, Yang W*. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020 Sep 10;11(1):4528.
16.    Lei X#, Dong X#, Ma R#, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F, Zhao Z, Zhou Z*, Xiang Z*, Wang J*. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020, 2020 Jul 30;11(1):3810.
17.    Han Z#, Rao J#, Xie Z#, Wang C, Xu B, Qian S, Wang Y, Zhu J, Yang B, Xu F, Lei X, Guo F, Zhao Z, Ren L*, Wang J*. Chemokine (C-X-C motif) Ligand 4 is a Restrictor of Respiratory Syncytial Virus Infection and an Indicator of Clinical Severity. Am J Respir Crit Care Med. 2020 Sep 1;202(5):717-729.
18.    Ou X#, Liu Y#, Lei X#, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q*，Wang J*，Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Commun. 2020, 11:1620.
19.    Pang X#, Ren L#, Wu S#, Ma W#, Yang J, Di L, Li J, Xiao Y, Kang L, Du S, Du J, Wang J, Li G, Zhai S, Chen L, Zhou W, Lai S, Gao L, Pan Y*, Wang Q*, Li M*, Wang J*, Huang Y*, Wang J*, COVID-19 Field Response Group, COVID-19 Laboratory Testing Group. Cold-chain food contamination as the possible origin of Covid-19 resurgence in Beijing.  Natl Sci Rev. 2020, 7(12), 1861–1864.
20.    Guo L#, Ren L#, Yang S#, Xiao M#, Chang D#, Yang F#, Dela Cruz C，Wang Y, Wu C，Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L*, Wang L*, Wang J*. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;7 1(15):778-785.
21.    Huang C#, Wang Y#, Li X#, Ren L#, Zhao J#, Hu Y#, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q，Wang J*, Cao B*. Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020，395(10223), 497-506.
22.    Ren L#, Wang Y, Wu ZQ#, Xiang Z#, Guo L#, Xu T#, Jiang Y#, Xiong Y#, Li Y, Li X, Li H, Fan GH, Gu X Xiao Y, Gao H, Xu J, Yang F, Wang X, Wu C, Chen L, Liu Y, Liu B, Yang J, Wang X, Dong J, Li L, Huang C, Zhao J, Hu Y, Cheng Z, Liu L, Qian Z, Qin C*, Jin Q*, Cao B*, Wang J*. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl).2020.133(9):1015-1024.
23.    Zhou Z#, Ren L#, Zhang L#, Zhong J#, Xiao Y#, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M*, Wang J*. Heightened innate immune response in COVID-19 cases. Cell Host Microbe. 2020, 27(6):883-890.e2.
24.    Wang C, Zhai X, Zhang X, Li L, Wang J*, Liu DP. Gene-edited babies: Chinese Academy of Medical Sciences' response and action. Lancet. 2019, 393(10166):25-26.
25.    Wang H#, Lei X#, Xiao X, Yang C, Lu W, Huang Z, Leng Q, Jin Q, He B, Meng G*, Wang J*. Reciprocal regulation between enterovirus 71 and the NLRP3 inflammasome. Cell Rep. 2015; 12：85.
26.    Lei X, Cui S, Zhao Z*, Wang J*. Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease. Natnl Science Rev, 2015,2 (3): 268-284 doi:10.1093 /nsr/nwv038 (Review)
27.    Zhou Z, Jia X, Xue Q, Dou Z, Ma Y, Zhao Z, Jiang Z, He B, Jin Q*, Wang J*. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proc Natl Acad Sci U S A, 2014, 111(2): E245-254. 
28.    Zhou Z, Cao M, Guo Y, Zhao L, Wang J,Jia X, Li J, Wang C, Gabriel G, Xue Q, Yi Y, Cui S, Jin Q*, Wang J*,Deng T*. Fragile X mental retardation protein stimulates ribonucleoprotein assembly of influenza A virus. Nat Commun, 2014, 5: 32-59. (IF 16.6)

（二）科(kē)技(jì )獎勵
1. 洪濤，王健偉. 戰勝瘟疫. 2003年第五屆全國(guó)優秀科(kē)普作(zuò)品圖書類三等獎.
2. 秦川，魏強，王健偉，等. SARS冠狀病毒感染恒河猴等動物(wù)的模型建立. 2004年北京市科(kē)學(xué)技(jì )術獎二等獎.
3. 秦川，魏強，王健偉，等. 動物(wù)生物(wù)安(ān)全實驗室保障技(jì )術平台的建立. 2012年中(zhōng)國(guó)實驗動物(wù)學(xué)會科(kē)學(xué)技(jì )術獎一等獎.
4. 王健偉、許文(wén)波等. 重要和新(xīn)發現呼吸道病毒的病原學(xué)研究及其應用(yòng). 2015年中(zhōng)華預防醫(yī)學(xué)會科(kē)學(xué)技(jì )術獎，一等獎.
5. 王健偉, 任麗麗, 等. 重要和新(xīn)發現呼吸道及腸道病毒的病原學(xué)研究及其應用(yòng). 2015年度高等學(xué)校科(kē)學(xué)研究優秀成果獎（科(kē)學(xué)技(jì )術）二等獎.
6. 黃芳，王健偉，等. 北京呼吸道傳染病病原體(tǐ)流行變異規律研究及其應用(yòng). 2019年度北京市科(kē)學(xué)技(jì )術進步獎二等獎

團隊累計培養研究生、博士後100餘人次